Session 3: Assessing the Immunologic Signature of Clinical Response

• Importance of multi-parameter analysis. What is the evidence? Will need to power studies for such endpoints.
  – Tumor signature
  – Peripheral blood signature
  – SNP signature

• What are the specimen types we all need to be collecting to facilitate novel assay development?
  – DNA, RNA, sera, PBMC, tumor?

• How do we integrate these analysis into current clinical trials?
  – All patients, subpopulations?